Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a global life science tools company with a strong focus on sustainability and a track record of successful self-help initiatives and transformative acquisitions. They have a solid growth outlook but face challenges in market conditions and product mix. Recent financials show improved operating margins and adjusted EPS, but there are potential risks such as decreased funding and competition in the protein analysis market.

Bears say

Bio-Techne is facing potential risks in the form of a delayed end market recovery, share loss to competitors who have been acquired, and potential disappointment in the progress of cell therapy development. Additionally, there is also a risk associated with the company's acquisition strategy and potential impact from a shift towards software/AI in the biotech industry. While biotech funding has increased in recent months, it has not yet translated into demand for the company's products. Despite this, Bio-Techne remains a global leader in life science tools and has the potential for growth in the future, leading to a price target of $73 from $62.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.